【Publication information】 Nicotine Addiction Treatment App With CO Checker Receives Regulatory Approval - CureApp, Inc.

We are pleased to inform you that the article has been published with the approval of our Nicotine Addiction Treatment App With CO Checker.

 



Bio Space

Asia’s First Prescription “Digital Therapeutic” Approved in Japan; Nicotine Addiction Treatment App With CO Checker Receives Regulatory Approval - CureApp, Inc. 

Comments

Post a Comment

Popular posts from this blog

CureApp Announces Results from World’s First Randomized Control Study for Digital Therapeutic Smoking Cessation App

Image
Tokyo, Japan – May 30, 2019 – Results from the world’s first randomized control study to examine digital therapeutic smoking cessation programs were presented on May 20th at the American Thoracic Society International Conference. The findings demonstrate that CureApp’s nicotine dependence treatment app resulted in an improvement in continuous abstinence rate (CAR) compared to a control group over multiple time points. Kohta Satake, M.D., M.B.A., M.P.H., Chief Executive Officer of CureApp, Inc. and a respiratory specialized physician says, "Healthcare professionals are challenged to help patients fight against the psychological nicotine addiction alone between clinical visits. CureApp’s digital therapeutics approach is a breakthrough in bridging the gap between clinical visits providing daily support to the patients. We are striving for regulatory and reimbursement approval to deliver the solution as soon as possible.” The CureApp solution delivers information and educational mater…
Read more

CureApp and its “Digital Therapeutics”, together with NASH (Non-Alcoholic Steatohepatitis) have launched multi-center clinical trials of their Digital Therapeutics.

Image
CureApp and its “Digital Therapeutics︎︎”, together with NASH (Non-Alcoholic Steatohepatitis)have launched multi-center clinical trials of their Digital Therapeutics. CureApp Co., Ltd (head office: Chuo-ku, Tokyo, President and CEO: Kohta Satake) in collaboration with Koike Kazuhiko and Assistant Professor Masaya Sato from the Department of Gastroenterology and Internal Medicine at the University of Tokyo Hospital, have been carrying out the research and development of “Digital Therapeutics”. We are pleased to inform you that we are starting multiple institutional clinical trials of the (NASH App) Digital Therapeutics, an application dedicated to the treatment of NASH (Non-Alcoholic Steatohepatitis).

This research follows the results of feasibility studies that have been conducted since 2016 at the University of Tokyo Hospital. It is a novel multi institutional clinical research project that has just begun and we aim to continue to obtain evidence to improve our product in a clinical se…
Read more

CureApp Inc., developing “Digital Therapeutics ”, starts joint-development and clinical research of Digital Therapeutics for hypertension with Jichi Medical University.

Image
CureApp Inc. (head office: Chuo-ku, Tokyo, President and CEO: Kota Satake) announced it starts joint-development and clinical research of "Digital Therapeutics" for hypertension with Professor Kazuomi Kario of Cardiovascular Medicine, Jichi Medical University. The clinical research explores the anti-hypertensive effects of the "Digital Therapeutics" and aims to create a novel treatment strategy for hypertension other than medication.

Background

CureApp Inc. aims to create a brand new treatment that is individually optimized (personalized) to achieve a higher therapeutic effect in light of mobile technology evolution. In particular, the scope of treatment encompasses patient awareness, habits and time out in the reach of conventional intervention, such as outside of hospital/clinic, at home, or out of workplace, overarching a wide variety of patients’ life. CureApp acknowledges uniqueness of patient’s individual status and aims to establish a mechanism of’ timely fol…
Read more